A bispecific antibody specifically binding to the two targets human CD3ɛ (further named also as 'CD3') and the extracellular domain of human ROR1 (further named also as 'ROR1'), characterized in that the bispecific antibody does not internalize in a cell based assay at 37°C during 2 hrs, using ROR1-positive B-CLL cells and used at an antibody concentration of 1 nM, whereby not internalize means, that the mean fluorescence intensity (MFI), as detected by flow cytometry, of a bispecific antibody upon binding to ROR1-positive primary B-CLL cells measured at time 0 is not reduced for more than 50%, preferably not more than 30% when re- measured after a 2hr-incubation at 37°C and which is useful for the treatment of B-cell malignancies like Chronic Lymphocytic Leukemia or plasma cell disorders like Multiple Myeloma MM or other B-cell disorders expressing ROR1 and ROR1-positive solid tumors.
BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1